MX2010008206A - Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf. - Google Patents

Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.

Info

Publication number
MX2010008206A
MX2010008206A MX2010008206A MX2010008206A MX2010008206A MX 2010008206 A MX2010008206 A MX 2010008206A MX 2010008206 A MX2010008206 A MX 2010008206A MX 2010008206 A MX2010008206 A MX 2010008206A MX 2010008206 A MX2010008206 A MX 2010008206A
Authority
MX
Mexico
Prior art keywords
klotho
compositions
methods
fusion polypeptides
fgf fusion
Prior art date
Application number
MX2010008206A
Other languages
English (en)
Inventor
Shou-Ih Hu
David Glass
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010008206A publication Critical patent/MX2010008206A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invención se refiere a método, kits, y composiciones para prevenir o tratar condiciones relacionadas con la edad o trastornos metabólicos. Los polipéptidos de fusión Klotho de la invención incluyen cuando menos una proteína Klotho o un fragmento activado de la misma. Las proteínas de fusión Klotho son útiles en el tratamiento y en la prevención de una variedad de condiciones relacionadas con la edad y trastornos metabólicos.
MX2010008206A 2008-01-28 2009-01-26 Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf. MX2010008206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6301508P 2008-01-28 2008-01-28
PCT/EP2009/050850 WO2009095372A1 (en) 2008-01-28 2009-01-26 Methods and compositions using klotho-fgf fusion polypeptides

Publications (1)

Publication Number Publication Date
MX2010008206A true MX2010008206A (es) 2010-08-10

Family

ID=40492768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008206A MX2010008206A (es) 2008-01-28 2009-01-26 Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.

Country Status (21)

Country Link
US (2) US8481031B2 (es)
EP (1) EP2247614B1 (es)
JP (1) JP5627469B2 (es)
KR (1) KR20100118126A (es)
CN (1) CN102015760B (es)
AR (1) AR070690A1 (es)
AU (1) AU2009209696B2 (es)
BR (1) BRPI0906722A2 (es)
CA (2) CA2854933A1 (es)
CL (1) CL2009000166A1 (es)
CO (1) CO6300826A2 (es)
CR (1) CR11580A (es)
EA (1) EA201001204A1 (es)
EC (1) ECSP10010372A (es)
ES (1) ES2479417T3 (es)
IL (1) IL207161A0 (es)
MA (1) MA32031B1 (es)
MX (1) MX2010008206A (es)
PE (1) PE20091405A1 (es)
TW (1) TW200936156A (es)
WO (1) WO2009095372A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
UA105016C2 (uk) 2008-10-10 2014-04-10 Амген Інк. Fgf21 мутанти і їх застосування
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
WO2010148142A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
MX368790B (es) * 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
EP2506861A1 (en) * 2009-12-02 2012-10-10 Amgen Inc. Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US8778887B2 (en) 2009-12-16 2014-07-15 Eli Lilly And Company Therapeutic uses of soluble alpha-Klotho
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
EA024755B1 (ru) * 2010-05-21 2016-10-31 ИксЭль-ПРОТЕИН ГМБХ Биосинтетические нерегулярные спиральные полипептиды пролина/аланина и их применения
PT3626257T (pt) * 2010-06-25 2021-11-12 Shire Human Genetic Therapies Métodos e composições de arilsulfatase a para a administração no snc
CN102465182A (zh) * 2010-10-29 2012-05-23 株式会社爱茉莉太平洋 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法
ES2748038T3 (es) 2011-07-01 2020-03-12 Ngm Biopharmaceuticals Inc Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
WO2013027191A1 (en) * 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
TWI478002B (zh) * 2012-02-09 2015-03-21 Univ Nat Sun Yat Sen 一種篩選治療或預防帕金森氏症及其併發症之候選藥物的方法
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
SG10202100667SA (en) * 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6159930B2 (ja) * 2013-10-24 2017-07-12 地方独立行政法人東京都健康長寿医療センター 筋幹細胞又は筋芽細胞、及びそれを用いた代謝変換に関与する物質のスクリーニング方法、並びにスクリーニング方法によって得られた物質を含む医薬組成物
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
JP6837840B2 (ja) 2014-01-24 2021-03-10 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
EP3122371A4 (en) * 2014-03-28 2017-09-06 New York University Fgf23 fusion proteins
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
AU2015335844B2 (en) 2014-10-23 2020-09-03 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
AU2015356643B2 (en) * 2014-12-04 2019-01-24 Novartis Ag Methods and compositions using Klotho variant polypeptides
CN105838661B (zh) * 2014-12-30 2020-11-10 深圳市第二人民医院 Klotho基因编辑在异种肾脏移植中的应用
CA2974988A1 (en) * 2015-02-06 2016-08-11 The Regents Of The University Of California Methods and compositions for improved cognition
US20180037868A1 (en) * 2015-02-27 2018-02-08 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cell expressing klotho
US11491115B2 (en) * 2015-07-09 2022-11-08 The Board Of Regents Of The University Of Texas System Nanoparticles containing extracellular matrix for drug delivery
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3377090B1 (en) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CA3025461A1 (en) * 2016-06-02 2017-12-07 Klotho Therapeutics, Inc. Therapeutic recombinant klotho proteins and compositions and methods involving the same
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
KR20230093531A (ko) 2016-11-22 2023-06-27 클로토 테라퓨틱스, 아이엔씨. 신규한 재조합 클로토 단백질 및 이를 수반하는 조성물 및 방법
EP3649157A4 (en) 2017-07-06 2021-07-28 Yale University COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF DISEASES RELATED TO ENDOCRINE FGF
JP7290340B2 (ja) * 2017-12-06 2023-06-13 クロトー セラピューティクス インコーポレイテッド クロトータンパク質レベルを評価および改善するための製品および方法
US20200331978A1 (en) * 2017-12-13 2020-10-22 Yale University Compositions and Methods for Treating or Preventing Endocrine FGF23-Linked Diseases
CN108434441A (zh) * 2018-04-17 2018-08-24 哈尔滨博翱生物医药技术开发有限公司 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用
CN109722480B (zh) * 2018-05-17 2022-04-26 上海交通大学 一种非小细胞肺癌检测试剂盒及其应用
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406A (en) 1849-05-01 Artificial teeth
US853A (en) 1838-07-24 Jesse reed
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
JP2571874B2 (ja) 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
AU646877B2 (en) 1990-06-15 1994-03-10 Scios Nova Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5541094A (en) * 1992-09-25 1996-07-30 E. I. Du Pont De Nemours And Company Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US6187992B1 (en) 1994-12-05 2001-02-13 Merck & Co., Inc. Transgenic mouse having a disrupted amyloid precursor protein gene
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US6194177B1 (en) 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
CA2244253C (en) 1996-03-15 2002-11-12 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
US6358752B1 (en) 1996-09-27 2002-03-19 Cornell Research Foundation, Inc. Liposome-enhanced test device and method
DE69737418T2 (de) 1996-12-26 2007-11-29 Kyowa Hakko Kogyo Co., Ltd. Protein mit der eigenschaft das altern zu unterdrücken
US6127598A (en) 1997-07-25 2000-10-03 The Regents Of The University Of California NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
US7060479B2 (en) * 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
DE60026287T2 (de) 1999-04-22 2006-08-17 Liposcience, Inc. Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
EP2075255A1 (en) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Human FGF-23 gene and gene expression products
AU2001273323B2 (en) 2000-07-19 2005-11-10 Advanced Research & Technology Institute Novel fibroblast growth factor (FGF23) and methods for use
CA2436661A1 (en) 2001-01-30 2002-08-08 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide molecules
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
JP2006240990A (ja) * 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
JP2006158339A (ja) * 2004-12-09 2006-06-22 Kyoto Univ βＫｌｏｔｈｏ遺伝子、Ｃｙｐ７ａ１遺伝子、及びそれらの利用
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009117622A2 (en) 2008-03-19 2009-09-24 Ambrx, Inc. Modified fgf-23 polypeptides and their uses
UA105016C2 (uk) 2008-10-10 2014-04-10 Амген Інк. Fgf21 мутанти і їх застосування
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules

Also Published As

Publication number Publication date
EA201001204A1 (ru) 2011-02-28
CN102015760B (zh) 2014-06-11
MA32031B1 (fr) 2011-01-03
CR11580A (es) 2010-10-05
AU2009209696B2 (en) 2012-04-19
US20130324458A1 (en) 2013-12-05
CA2712634C (en) 2014-09-16
EP2247614A1 (en) 2010-11-10
US9458209B2 (en) 2016-10-04
CO6300826A2 (es) 2011-07-21
CL2009000166A1 (es) 2010-12-24
US20090192087A1 (en) 2009-07-30
CN102015760A (zh) 2011-04-13
CA2712634A1 (en) 2009-08-06
BRPI0906722A2 (pt) 2015-07-07
KR20100118126A (ko) 2010-11-04
WO2009095372A1 (en) 2009-08-06
TW200936156A (en) 2009-09-01
ES2479417T3 (es) 2014-07-24
CA2854933A1 (en) 2009-08-06
AU2009209696A1 (en) 2009-08-06
ECSP10010372A (es) 2010-08-31
IL207161A0 (en) 2010-12-30
PE20091405A1 (es) 2009-10-07
AR070690A1 (es) 2010-04-28
US8481031B2 (en) 2013-07-09
JP2011510620A (ja) 2011-04-07
JP5627469B2 (ja) 2014-11-19
EP2247614B1 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
MX2009012623A (es) Moduladores de cinasa heterociclicos.
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
MX336391B (es) Metodos y composiciones que usan polipeptidos de fusion de fgf23.
TW200833692A (en) Triazolopyridazine protein kinase modulators
EA201170349A1 (ru) Модуляторы mif
NZ603570A (en) Biological materials related to her3
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
SG169327A1 (en) Compositions and methods of use for antibodies of dickkopf-1 and/or -4
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX2007001638A (es) Proteinas de fusion del dominio de unión.
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
WO2010130830A3 (en) Anti-sclerostin vhh and their use for treating bone diseases
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
WO2011134084A8 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
EA201100071A1 (ru) Новые композиции и способы
EA201290069A1 (ru) Модифицированные полипептиды фактора ix и их применения
WO2009098682A3 (en) Methods and compositions for treatment of mitochondrial disorders
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration